$BBIO
SEC EDGAR Filings Hub
2 Filings
$BBIO · BridgeBio Pharma, Inc. SEC Filings
Position Tracker tracks 2 SEC EDGAR filings for BridgeBio Pharma, Inc. ($BBIO) from October 29, 2026 through October 29, 2026, including 0 Form 10-K annual reports, 1 Form 10-Q quarterly earnings reports, 1 Form 8-K current event disclosures, and 0 Form 4 insider equity transactions. Select any filing below to read the full AI summary, key financial takeaways, and original SEC.gov document.
Check $BBIO portfolio concentration →
View $BBIO Congress trades →
Research $BBIO stock →
All SEC filings →
Total Filings2
10-K / 10-Q Reports1
8-K Material Events1
Form 4 Insider0
High-Impact2
Latest FilingOctober 29, 2026
Browse SEC Filings by Form Type
Latest $BBIO SEC Filings & AI Summaries (2)
October 29, 2026
$BBIO 10-Q — BridgeBio Pharma, Inc.
BridgeBio's near-breakeven quarter validates the Attruby commercial thesis and signals the rare-disease platform may self-fund its pipeline without additional dilutive financing.
October 29, 2026
$BBIO 8-K — BridgeBio Pharma, Inc.
BridgeBio is executing a rare biotech triple: a commercial launch ramping to near-profitability while three first-in-class therapies face FDA decisions within seven months, back…